Published in J Infect Dis on February 01, 2005
Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med (2007) 2.56
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med (2006) 2.10
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer (2007) 1.45
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics (2012) 1.10
Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer (2011) 1.03
The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model. Vaccine (2011) 1.00
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2007) 0.96
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health (2009) 0.94
Incremental benefits of male HPV vaccination: accounting for inequality in population uptake. PLoS One (2014) 0.86
Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2010) 0.86
Estradiol improves genital herpes vaccine efficacy in mice. Vaccine (2009) 0.85
HPV-vaccination against cervical carcinoma: will it really work? Med Microbiol Immunol (2007) 0.84
Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran. Iran J Pharm Res (2014) 0.83
Too much of a good thing? When to stop catch-up vaccination. Med Decis Making (2013) 0.82
Type-specific human papillomavirus biological features: validated model-based estimates. PLoS One (2013) 0.82
Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. Infect Agent Cancer (2014) 0.81
Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries. Infect Dis Obstet Gynecol (2011) 0.81
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. Pharmacoeconomics (2016) 0.81
HPV related diseases in males: a heavy vaccine-preventable burden. J Prev Med Hyg (2013) 0.79
Community-based interventions to improve HPV vaccination coverage among 13- to 15-year-old females: measures implemented by local governments in Japan. PLoS One (2013) 0.78
Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies. PLoS One (2012) 0.78
Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother (2015) 0.75
Applying a Simple Model of Cost Effectiveness Study of HPV Vaccine for Iran. Iran J Pharm Res (2015) 0.75
Infection transmission and chronic disease models in the study of infection-associated cancers. Br J Cancer (2013) 0.75
Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. Emerg Infect Dis (2016) 0.75
Human papillomavirus vaccine acceptance among young men in Bangalore, India. Int J Dermatol (2014) 0.75
The human papillomavirus vaccine: The promise of cervical cancer prevention. Can J Infect Dis Med Microbiol (2007) 0.75
A home-school-doctor model to break the barriers for uptake of human papillomavirus vaccine. BMC Public Health (2015) 0.75
Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clin Infect Dis (2016) 0.75